Electrophysiology and arrhythmogenic activity of single cardiomyocytes from canine superior vena cava.
BACKGROUND
The superior vena cava (SVC) has been proved to be a focal point in the initiation of paroxysmal atrial fibrillation. The autonomic nervous system plays an important role in the genesis of atrial fibrillation. However, the arrhythmogenic potentials of SVC and its responses to autonomic agents are not clear. The purpose of this study was to isolate single SVC cardiomyocytes and to investigate their electrophysiological characteristics, as well as the direct effects of autonomic agents.


RESULTS
Canine SVC cardiomyocytes were isolated by perfusion with digestive enzymes. The action potentials and ionic currents were investigated in single SVC cardiomyocytes using the whole-cell clamp technique. Dissociation of the SVC yielded rod-shaped single cardiomyocytes with (n=74, 51%) or without (n=71, 49%) pacemaker activities. There were similar densities of inward Ca2+, delayed rectifier K+, transient inward, inward rectifier K+, and pacemaker currents between SVC cardiomyocytes with and without pacemaker activity. SVC cardiomyocytes with pacemaker activity have, however, greater transient outward currents than those without pacemaker activity. In SVC cardiomyocytes, acetylcholine (5.5 micromol/L) abolished the spontaneous activities, but isoproterenol (10 nmol/L), atropine (10 micromol/L), and phenylephrine (10 micromol/L) accelerated the spontaneous activity and induced the occurrences of early or delayed afterdepolarizations.


CONCLUSIONS
These findings suggest that SVC cardiomyocytes have distinct action potentials and ionic current profiles that may be responsible for the arrhythmogenic activity of the SVC.
Chen
Yi-Jen
YJ
Taipei Medical University, Wan-Fang Hospital, Taipei, Taiwan.
Chen
Yao-Chang
YC
Yeh
Hung-I
HI
Lin
Cheng-I
CI
Chen
Shih-Ann
SA
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000209:etiology; D001337:Autonomic Agents / Q000494:pharmacology*; D001683:Biological Clocks / Q000502:physiology; D002118:Calcium / Q000378:metabolism; D002469:Cell Separation; D051668:Delayed Rectifier Potassium Channels; D004285:Dogs; D022062:Electrophysiologic Techniques, Cardiac; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D009206:Myocardium / Q000166:cytology* / Q000378:metabolism; D018408:Patch-Clamp Techniques; D011188:Potassium / Q000378:metabolism; D015221:Potassium Channels / Q000378:metabolism; D024642:Potassium Channels, Voltage-Gated; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology; D014683:Vena Cava, Superior / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D001337:Autonomic Agents; D051668:Delayed Rectifier Potassium Channels; D018727:Muscarinic Antagonists; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D011188:Potassium; D002118:Calcium